Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cranberry supplement claims for bladder infection treatment draw FDA letters of objection.

This article was originally published in The Tan Sheet

Executive Summary

CRANBERRY BLADDER INFECTION CLAIMS GENERATE LETTERS OF OBJECTION from FDA to two firms -- Nature's Life and Nature's Way -- in late April and early June, designating the statements as drug claims. Springfield, Utah-based Nature's Way had submitted the structure/function claim "Promotes normal urinary tract health...to maintain a healthy urinary tract by inhibiting bacterial adhesion to the lining of the bladder" for its product, Concentrated Cranberry Fruit. However, the June 3 FDA "courtesy" letter says, "The statement that you are making for this product suggests that it is intended to treat, prevent, cure or mitigate disease, namely bladder infections caused by pathogenic microorganisms."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel